Regeneron shares preliminary results showing gene therapy improves auditory responses in child with profound genetic hearing loss

Global phase 1/2 chord trial investigating otoferlin gene therapy (db-oto) represents regeneron's first auditory program and is currently enrolling patients
REGN Ratings Summary
REGN Quant Ranking